Market Closed -
OTC Markets
01:20:54 03/07/2024 am IST
5-day change
1st Jan Change
0.44
USD
+25.36%
-2.22%
-58.49%
PetVivo Holdings, Inc. Announces Board Appointments
June 21, 2019 at 01:46 am IST
PetVivo Holdings, Inc. elected Scott M. Johnson, Gregory D. Cash and James R. Martin as directors.
Transcript : PetVivo Holdings, Inc., Q4 2024 Earnings Call, Jun 28, 2024
29/06
PetVivo Holdings, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024
29/06
CI
PetVivo Holdings, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024
29/06
CI
PetVivo Holdings, Inc. announced that it has received $1.0975 million in funding
07/05
CI
PetVivo Holdings, Inc.(OTCPK:PETV) dropped from S&P TMI Index
11/04
CI
PetVivo Holdings, Inc. announced that it has received $0.3 million in funding from A.L. Sarroff Management, LLC
10/04
CI
PetVivo Holdings, Inc. announced that it expects to receive $1.0975 million in funding
09/04
CI
PetVivo Holdings, Inc.(OTCPK:PETV) dropped from NASDAQ Composite Index
08/04
CI
PetVivo, ThinkEquity Terminate At-The-Market Offering Deal
11/03
MT
PetVivo Names Garry Lowenthal its New Chief Financial Officer
11/03
MT
Petvivo Holdings, Inc. Appoints Garry Lowenthal as Its New Chief Financial Officer
11/03
CI
Transcript : PetVivo Holdings, Inc., Q3 2024 Earnings Call, Feb 12, 2024
13/02
PetVivo Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
13/02
CI
Earnings Flash (PETV) PETVIVO HOLDINGS Posts Q3 Revenue $595,891
13/02
MT
PetVivo Holdings, Inc. Announces Release of Clinical Study Results Involving Feline Tolerance to Intra-Articular Injections of Spryng? with Osteocushion? Technology
07/02
CI
PetVivo Holdings, Inc. Announces Release of Clinical Study Results Involving Canine Tolerance to Intra-Articular Injections of Spryng with OsteoCushion Technology
31/01
CI
Robert J. Folkes Resigns as Chief Financial Officer of PetVivo Holdings, Inc., Effective from February 2, 2024
26/01
CI
Petvivo Receives Notice of Allowance from United States Patent and Trademark Office for Key Patent Application
23/01
CI
PetVivo Holdings, Inc. Approves Election of Diane Levitan as Member of the Board
23/11
CI
Transcript : PetVivo Holdings, Inc., Q2 2024 Earnings Call, Nov 14, 2023
15/11
Earnings Flash (PETV) PETVIVO HOLDINGS Reports Q2 Revenue $207.4M
15/11
MT
PetVivo Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
15/11
CI
Leslie Coolidge and Scott Johnson Not to Stand for Re-Election as Board Directors of PetVivo Holdings, Inc
04/23/04
CI
Sector Update: Health Care Stocks Slipping Late Afternoon
25/23/25
MT
Sector Update: Health Care Stocks Lower Thursday Afternoon
24/23/24
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
PetVivo Holdings, Inc. is a biomedical device company. The Company is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for animals. The Companyâs lead product Spryng with OsteoCushion Technology, is a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The Company is primarily engaged in the business of commercializing and licensing products in the veterinary market to treat and/or manage afflictions of companion animals, such as dogs and horses. Its products are derived from biomaterials that simulate a bodyâs cellular tissue by virtue of their reliance upon natural protein and carbohydrate compositions, which incorporate such tissue building blocks as collagen, elastin, and proteoglycans such as heparin. The Company has a pipeline of therapeutic devices for both veterinary and human clinical applications.
More about the company
Last Close Price
0.44
USD
Average target price
5
USD
Spread / Average Target
+1,036.36%
Consensus
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
PETVIVO HOLDINGS, INC. 
